Trends in overall opportunistic illnesses, Pneumocystis carinii pneumonia, cerebral toxoplasmosis and Mycobacterium avium complex incidence rates over the 30 years of the HIV epidemic: A systematic review

Brazilian Journal of Infectious Diseases

Volumn 18, Issue 2, 2014, Pages 196-210

  Coelho, Lara ^a   Veloso, Valdiléa Gonçalves ^a   Grinsztejn, Beatriz ^a   Luz, Paula Mendes ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Acquired immunodeficiency syndrome; AIDS related opportunistic infections; Incidence; Opportunistic infection

Indexed keywords

ATYPICAL MYCOBACTERIOSIS; BRAZIL; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; INFECTION RATE; MORBIDITY; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; SHORT SURVEY; SYSTEMATIC REVIEW; TOXOPLASMOSIS; TREND STUDY; AIDS RELATED COMPLEX; DISEASE SURVEILLANCE; HIGH INCOME SETTING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INCIDENCE; LOWEST INCOME GROUP; MIDDLE INCOME SETTING; MULTICENTER STUDY (TOPIC); MYCOBACTERIUM AVIUM COMPLEX; SOCIAL STATUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; INCIDENCE; OPPORTUNISTIC INFECTION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; EPIDEMICS; HUMANS; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PNEUMONIA, PNEUMOCYSTIS; TOXOPLASMOSIS, CEREBRAL;

EID: 84897646082     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2013.10.003     Document Type: Short Survey

References (45)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2012; 2012.
2. Buchacz K., Baker R.K., Palella F.J., Chmiel J.S., Lichtenstein K.A., Novak R.M., et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010, 24:1549-1559.
3. Pacheco A.G., Tuboi S.H., May S.B., Moreira L.F.S., Ramadas L., Nunes E.o.P., et al. Temporal changes in causes of death among HIV-infected patients in the HAART Era in Rio de Janeiro, Brazil. J. Acquir. Immune Defic. Syndr. 2009, 51:624-630. 10.1097/QAI.0b013e3181a4ecf5.
4. Grinsztejn B., Luz P.M., Pacheco A.G., Santos D.V., Velasque L., Moreira R.I., et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One 2013, 8:e59768.
5. Perbost I., Malafronte B., Pradier C., Santo L.D., Dunais B., Counillon E., et al. In the era of highly active antiretroviral therapy, why are HIV-infected patients still admitted to hospital for an inaugural opportunistic infection?. HIV Med. 2005, 6:232-239.
6. Cardoso S.W., Grinsztejn B., Velasque L., Veloso V.G., Luz P.M., Friedman R.K., et al. Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil. AIDS Res. Hum. Retroviruses 2010, 26:865-874.
7. Hacker M.A., Kaida A., Hogg R.S., Bastos F.I. The first ten years: achievements and challenges of the Brazilian program of universal access to HIV/AIDS comprehensive management and care, 1996-2006. Cad. Saude Publica 2007, 23(Suppl 3):S345-S359.
8. Nemes M.I., Carvalho H.B., Souza M.F. Antiretroviral therapy adherence in Brazil. AIDS 2004, 18(Suppl 3):S15-S20.
9. Clavel F., Hance A.J. HIV drug resistance. N. Engl. J. Med. 2004, 350:1023-1035.
10. Mocroft A., Katlama C., Johnson A.M., Pradier C., Antunes F., Mulcahy F., et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000, 356:291-296.
11. San-Andres F.J., Rubio R., Castilla J., Pulido F., Palao G., de Pedro I., et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin. Infect. Dis. 2003, 36:1177-1185.
12. Rojanawiwat A., Tsuchiya N., Pathipvanich P., Pumpradit W., Schmidt W.-P., Honda S., et al. Impact of the National Access to Antiretroviral Program on the incidence of opportunistic infections in Thailand. International Health 2011, 3:101-107.
13. Fonseca L.A., Reingold A.L., Casseb J.R., Brigido L.F., Duarte A.J. AIDS incidence and survival in a hospital-based cohort of asymptomatic HIV seropositive patients in Sao Paulo, Brazil. Int. J. Epidemiol. 1999, 28:1156-1160.
14. Casseb J., Fonseca L.A., Veiga A.P., de Almeida A., Bueno A., Ferez A.C., et al. AIDS incidence and mortality in a hospital-based cohort of HIV-1-seropositive patients receiving highly active antiretroviral therapy in Sao Paulo, Brazil. AIDS Patient Care STDS 2003, 17:447-452.
15. Gadelha A.J., Accacio N., Costa R.L., Galhardo M.C., Cotrim M.R., de Souza R.V., et al. Morbidity and survival in advanced AIDS in Rio de Janeiro, Brazil. Rev. Inst. Med. Trop. Sao Paulo 2002, 44:179-186.
16. Mocroft A., Sabin C.A., Youle M., Madge S., Tyrer M., Devereux H., et al. Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. J. Acquir. Immune Defic. Syndr. 1999, 21:401-407.
17. Schwarcz L., Chen M.J., Vittinghoff E., Hsu L., Schwarcz S. Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance. AIDS 2013, 27:597-605.
18. Hung C.C., Chen M.Y., Hsieh S.M., Sheng W.H., Chang S.C. Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study. J. Acquir. Immune Defic. Syndr. 2000, 24:378-385.
19. Sacktor N., Lyles R.H., Skolasky R., Kleeberger C., Selnes O.A., Miller E.N., et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001, 56:257-260.
20. Ledergerber B., Egger M., Erard V., Weber R., Hirschel B., Furrer H., et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. J Am Med Assoc 1999, 282:2220-2226.
21. Garvey L., Winston A., Walsh J., Post F., Porter K., Gazzard B., et al. HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur. J. Neurol. 2011, 18:527-534.
22. Badri M., Maartens G., Bekker L.G., Wood R. The spectrum and prognosis of AIDS-defining illnesses in Cape Town. S Afric J HIV Med 2005, 6:11-16.
23. Rossi M., Flepp M., Telenti A., Schiffer V., Egloff N., Bucher H., et al. Disseminated M. avium complex infection in the Swiss HIV Cohort Study: declining incidence, improved prognosis and discontinuation of maintenance therapy. Swiss Med. Wkly. 2001, 131:471-477.
24. Bonard D., Messou E., Seyler C., Vincent V., Gabillard D., Anglaret X. High incidence of atypical mycobacteriosis in African HIV-infected adults with low CD4 cell counts: a 6-year cohort study in Cote d'Ivoire. AIDS 2004, 18:1961-1964.
25. Gadelha A., Accacio N., Grinzstejn B., Veloso V., da Silveira L.B., Fandinho F., et al. Low incidence of colonization and no cases of disseminated Mycobacterium avium complex infection (DMAC) in Brazilian AIDS patients in the HAART Era. Braz. J. Infect. Dis. 2002, 6:252-257.
26. Yazdanpanah Y., Chene G., Losina E., Goldie S.J., Merchadou L.D., Alfandari S., et al. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int. J. Epidemiol. 2001, 30:864-871.
27. Cain L.E., Cole S.R., Greenland S., Brown T.T., Chmiel J.S., Kingsley L., et al. Effect of highly active antiretroviral therapy on incident AIDS using calendar period as an instrumental variable. Am. J. Epidemiol. 2009, 169:1124-1132.
28. 3. Multicenter AIDS Cohort Study. J. Infect. Dis. 1994, 170:1284-1287.
29. Baril L., Jouan M., Agher R., Cambau E., Caumes E., Bricaire F., et al. Impact of highly active antiretroviral therapy on onset of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS. AIDS 2000, 14:2593-2596.
30. Brodt H.R., Kamps B.S., Gute P., Knupp B., Staszewski S., Helm E.B. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997, 11:1731-1738.
31. Chaisson R.E., Moore R.D., Richman D.D., Keruly J., Creagh T. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am. Rev. Respir. Dis. 1992, 146:285-289.
32. Charurat M., Blattner W., Hershow R., Buck A., Zorrilla C.D., Watts D.H., et al. Changing trends in clinical AIDS presentations and survival among HIV-1-infected women. J Womens Health (Larchmt) 2004, 13:719-730.
33. De Beaudrap P., Etard J.F., Diouf A., Ndiaye I., Ndeye G.F., Sow P.S., et al. Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort. BMC Infect. Dis. 2010, 10:179.
34. Forrest D.M., Seminari E., Hogg R.S., Yip B., Raboud J., Lawson L., et al. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin. Infect. Dis. 1998, 27:1379-1385.
35. Holmes C.B., Wood R., Badri M., Zilber S., Wang B., Maartens G., et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J. Acquir. Immune Defic. Syndr. 2006, 42:464-469.
36. Kaplan J.E., Hanson D., Dworkin M.S., Frederick T., Bertolli J., Lindegren M.L., et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 2000, 30(Suppl 1):S5-S14.
37. Kirk O., Gatell J.M., Mocroft A., Pedersen C., Proenca R., Brettle R.P., et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am. J. Respir. Crit. Care Med. 2000, 162(3 Pt 1):865-872.
38. Losina E., Yazdanpanah Y., Deuffic-Burban S., Wang B., Wolf L.L., Messou E., et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d'Ivoire. Antivir. Ther. 2007, 12:543-551.
39. Mocroft A., Youle M., Phillips A.N., Halai R., Easterbrook P., Johnson M.A., et al. The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Arch. Intern. Med. 1998, 158:491-497.
40. Moore R.D., Chaisson R.E. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann. Intern. Med. 1996, 124:633-642.
41. Moorman A.C., Von Bargen J.C., Palella F.J., Holmberg S.D. Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998, 19:182-188.
42. Plettenberg A., Brockmeyer N.H., Haastert B., Michalik C., Dupke S., Schewe K., et al. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS. Infection 2011, 39:3-12.
43. Podlasin R.B., Wiercinska-Drapalo A., Olczak A., Beniowski M., Smiatacz T., Malolepsza E., et al. Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002. Infection 2006, 34:196-200.
44. Riveiro-Barciela M., Falco V., Burgos J., Curran A., Van den Eynde E., Navarro J., et al. Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital. HIV Med. 2013, 14:21-30.
45. Wohl A.R., Lu S., Turner J., Kovacs A., Witt M., Squires K., et al. Risk of opportunistic infection in the HAART era among HIV-infected Latinos born in the United States compared to Latinos born in Mexico and Central America. AIDS Patient Care STDS 2003, 17:267-275.